USP Map Charts Way To Medicine Supply Resiliency
Executive Summary
Supply chain project shows which drug products are at greatest risk in different scenarios – and which responses would do the most to prevent shortages. Officials from the pharmacopoeial group share how it works and what it can do to help bake in resilience against pandemics, natural disasters, trade wars and shooting wars.
You may also be interested in...
China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says
USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.
Did Product Quality Decline While US FDA Inspectors Were Away?
Academics assert more should be done to restore pre-pandemic site-inspection activity levels, especially abroad, following analysis of 10 years of data on US FDA inspection trends, costs and resources published in Health Affairs.
US FDA’s OPQ Reshapes For More Nimble Approach To Drug Quality Reviews
Reorganization in January expected to leave CDER’s nine-year-old pharmaceutical quality assessment organization more adaptable to public health emergencies, new pharmaceutical technologies and market dynamics, while further blending approaches to new and generic drug reviews.